• Rani S Sellers, Keith Nelson, Bindu Bennet, Jayanthi Wolf, Niraj Tripathi, Ronnie Chamanza, Marie-France Perron Lepage, Karissa Adkins, Sebastien Laurent, and Sean P Troth.
• Pfizer Inc, Pearl River, New York, NY, USA.
• Toxicol Pathol. 2020 Feb 1; 48 (2): 257-276.

AbstractThe design and execution of toxicology studies supporting vaccine development have some unique considerations relative to those supporting traditional small molecules and biologics. A working group of the Society of Toxicologic Pathology Scientific and Regulatory Policy Committee conducted a review of the scientific, technical, and regulatory considerations for veterinary pathologists and toxicologists related to the design and evaluation of regulatory toxicology studies supporting vaccine clinical trials. Much of the information in this document focuses on the development of prophylactic vaccines for infectious agents. Many of these considerations also apply to therapeutic vaccine development (such as vaccines directed against cancer epitopes); important differences will be identified in various sections as appropriate. The topics addressed in this Points to Consider article include regulatory guidelines for nonclinical vaccine studies, study design (including species selection), technical considerations in dosing and injection site collection, study end point evaluation, and data interpretation. The intent of this publication is to share learnings related to nonclinical studies to support vaccine development to help others as they move into this therapeutic area. [Box: see text].

22 keywords...

hide…